Advertisement

International Journal of Hematology

, Volume 75, Issue 1, pp 95–99 | Cite as

Successful Use of Recombinant Factor VIIa for Hemostasis During Total Knee Replacement in a Severe Hemophiliac with High-Titer Factor VIII Inhibitor

  • Marcus E. Carr
  • Thomas P. Loughran
  • John A. Cardea
  • Wade K. Smith
  • Jan G. Kuhn
  • Maribeth V. Dottore
Case Report

Abstract

A 32-year-old male patient with severe factor VIII (FVIII) deficiency had developed a high-titer FVIII inhibitor at age 13. Recurrent hemarthroses caused bony destruction in both knees, significantly impairing his ability to walk. Knee examination revealed 20 degrees of varus, destruction of the medial joint line, and flexion contracture. Total knee arthroplasty was performed using recombinant factor VIIa (rFVIIa, NovoSeven) for hemostatic control. rFVIIa (85 μg/kg given intravenously over 3-5 minutes) was given just prior to surgery. The dose was repeated every 2 hours during and for the first 48 hours after surgery. When the tourniquet was removed, rFVIIa had not been infused for 1.5 hours, and significant hemorrhage was noted. The hemorrhage responded promptly to rFVIIa infusion. The infusion interval was extended to every 4 hours for an additional 48 hours, and subsequent doses were given every 6 hours until the patient returned to the clinic 2 days postdischarge. Hemoglobin levels dropped from 16.9 gm/dL on admission to 9.1 gm/dL at discharge. After 2 months, the patient returned to work. We recommend that tourniquet release be performed immediately after rFVIIa administration and that aggressive physical therapy be considered in the early postoperative period when rFVIIa infusions are frequent.

Key words

Hemophilia Factor VIII inhibitor Total knee replacement NovoSeven Hemarthropathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thomason HC III, Wilson FC, Lachiewicz PF, Kelley SS. Knee arthroplasty in hemophilic arthropathy.Clin Orthop. 1999;360:169–173.CrossRefGoogle Scholar
  2. 2.
    Karthaus RP, Novakova IR. Total knee replacement in haemophilic arthropathy.J Bone Joint Surg Br. 1988;70:382–385.CrossRefPubMedGoogle Scholar
  3. 3.
    Birch NC, Ribbans WJ, Goldman E, Lee CA. Knee replacement in haemophilia.J Bone Joint Surg Br. 1994;76:165–166.CrossRefPubMedGoogle Scholar
  4. 4.
    Figgie MP, Goldberg VM, Figgie HE, et al. Total knee arthroplasty for the treatment of chronic hemophilic arthropathy.Clin Orthop. 1989;248:98–107.Google Scholar
  5. 5.
    Goldberg VM, Heiple KG, Ratnoff OD, et al. Total knee arthro- plasty in classic haemophilia.J Bone Joint Surg Br. 1981;63A:695–701.CrossRefGoogle Scholar
  6. 6.
    Kjaersgaard-Andersen P, Christiansen SE, Ingerslev J, Sneppen O. Total knee arthroplasty in classic hemophilia.Clin Orthop. 1990;256:137–146.Google Scholar
  7. 7.
    Lachievicz PF, Inglis AE, Insall JI, et al. Total knee arthroplasty in hemophilia.J Bone Joint Surg Br. 1985;67A:1361–1366.CrossRefGoogle Scholar
  8. 8.
    Luck JV, Kasper CK. Surgical management of advanced haemophilic arthropathy.Clin Orthop. 1988;242:60–82.Google Scholar
  9. 9.
    Magone JB, Dennis DA, Weis LD. Total knee arthroplasty in chronic hemophilic arthropathy.Orthopedics. 1986;9:653–657.PubMedGoogle Scholar
  10. 10.
    McCollough NC, Enis JE, Lovitt J, et al. Synovectomy or total replacement of the knee in hemophilia.J Bone Joint Surg Br. 1979;61A:69–75.CrossRefGoogle Scholar
  11. 11.
    Rana NA, Shapiro GR, Green D. Long term follow-up of prosthetic joint replacement in hemophilia.Am J Hematol. 1986;23:329–337.CrossRefPubMedGoogle Scholar
  12. 12.
    Small M, Steven MM, Freeman PA, et al. Total knee arthroplasty in hemophilic arthritis.J Bone Joint Surg Br. 1983;65B:163–165.CrossRefGoogle Scholar
  13. 13.
    Teigland JC, Tjonnfjord GE, Evensen SA, et al. Knee arthroplasty in hemophilia, 5-12 year follow-up of 15 patients.Acta Orthop Scand. 1993;64:153–156.CrossRefPubMedGoogle Scholar
  14. 14.
    Beeton K, Rodriguez-Merchan ED, Alltree J. Total joint arthro- plasty in haemophilia.Haemophilia. 2000;6:474–481.CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement in haemophilia A.Haemophilia. 2000;6:104–109.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Schick M, Stucki G, Rodriguez M, et al. Haemophilic arthropathy: assessment of quality of life after total knee arthroplasty.Clin Rheumatol. 1999;18:468–472.CrossRefPubMedGoogle Scholar
  17. 17.
    Heeg M, Meyer K, Smid WM, et al. Total knee and hip arthroplasty in haemophilic patients.Haemophilia. 1998;4:747–751.CrossRefPubMedGoogle Scholar
  18. 18.
    Hoyer WL. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reis- ner HM, White GC II, eds.Inhibitors to Coagulation Factors. New York, NY: Plenum Press; 1995:35–45.CrossRefGoogle Scholar
  19. 19.
    Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.Thromb Haemost. 1998;80:773–778.CrossRefPubMedGoogle Scholar
  20. 20.
    Brettler D. Inhibitors to factor VIII and IX.Haemophilia. 1995;1:35–39.CrossRefPubMedGoogle Scholar
  21. 21.
    Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.Thromb Haemost. 1999;82:531–539.CrossRefPubMedGoogle Scholar
  22. 22.
    Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemo-philic patients with factor VIII and factor IX inhibitors.Semin Thromb Hemost. 2000;26:425–432.CrossRefPubMedGoogle Scholar
  23. 23.
    Menart C, Cognet V, Petit PY, et al. Management of an anti-factor VIII inhibitor occurring during surgical procedure with continuous infusion of Novoseven.Blood Coagul Fibrinolysis. 1998;9:289–290.CrossRefPubMedGoogle Scholar
  24. 24.
    Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in patients with severe hemophilia A during synovec- tomy.Lancet. 1988;2:1193.CrossRefPubMedGoogle Scholar
  25. 25.
    Ingerslev J, Freidman D, Gastineau D, et al. Major surgery in haemophiliac patients with inhibitors using recombinant factor VIIa.Haemostasis. 1996;26:18–23.Google Scholar
  26. 26.
    O’Marcaigh AS, Schmalz BJ, Shaughnessy WJ, Gilchrist GS. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor.Mayo Clin Proc. 1994;69:641–644.CrossRefPubMedGoogle Scholar
  27. 27.
    Negrier C, Hay CRM. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.Semin Thromb Hemost. 2000;26:407–412.CrossRefPubMedGoogle Scholar
  28. 28.
    Schulman S, d’Orion R, Martinowitz U, et al. Experiences with continuous infusion of recombinant activated factor VII.Blood Coagul Fibrinolysis. 1998;9(suppl 1):S97-S101.PubMedGoogle Scholar
  29. 29.
    Gallistl S, Cvirn G, Muntean W. Recombinant factor VIIa does not induce hypercoagulability in vitro.Thromb Haemost. 1999;81:245–249.CrossRefPubMedGoogle Scholar
  30. 30.
    Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII- platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia.Semin Thromb Hemost. 2000;26:373–377.CrossRefPubMedGoogle Scholar
  31. 31.
    Kjalke M, Ezban M, Monroe DM, et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.Br J Haematol. 2001;114:114–120.CrossRefPubMedGoogle Scholar
  32. 32.
    Carr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering.Biopolymers. 1977;16:1–15.CrossRefPubMedGoogle Scholar
  33. 33.
    Carr ME Jr, Hermans J. Size and density of fibrin fibers from turbidity.Macromolecules. 1978;11:46–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Blomback B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity.Biochim Biophys Acta. 1989;997:96–110.CrossRefPubMedGoogle Scholar
  35. 35.
    Bale MD, Ferry JD. Strain enhancement of elastic modulus in fine fibrin clots.Thromb Res. 1988;52:565–572.CrossRefPubMedGoogle Scholar
  36. 36.
    Carr ME Jr, Zekert SL. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma.Am J Physiol. 1994;266:H1195-H1201.PubMedGoogle Scholar
  37. 37.
    Gabriel DA, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis.J Biol Chem. 1992;267:24259–24263.PubMedGoogle Scholar
  38. 38.
    Carr ME Jr, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma.J Lab Clin Med. 1996;128:83–88.CrossRefPubMedGoogle Scholar
  39. 39.
    Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.Arterioscler Thromb Vasc Biol. 2000;20:1354–1361.CrossRefPubMedGoogle Scholar
  40. 40.
    Mullin JL, Norfolk SE, Weisel JW, Lord ST. Clot lysis of variant recombinant fibrinogens confirms that fiber diameter is a major determinant of lysis rate.Ann NY Acad Sci. 2001;936:331–334.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Marcus E. Carr
    • 1
  • Thomas P. Loughran
    • 1
  • John A. Cardea
    • 1
  • Wade K. Smith
    • 1
  • Jan G. Kuhn
    • 1
  • Maribeth V. Dottore
    • 1
  1. 1.Departments of Orthopedic SurgeryPathology, and Internal Medicine and the Central Virginia Coagulation Disorders Center of MCV Hospitals and Virginia Commonwealth UniversityRichmond, VirginiaUSA

Personalised recommendations